A2B-395

N/A

Report date: 2025/06/06 20:01:13

Base Information

Drug NameA2B-395
Drug Alias NameAllogeneic logic-gated Tmod CAR T cells therapy (A2 Biotherapeutics)Tmod CAR T-cell Therapy (A2 Biotherapeutics)A2B395A2B-395
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsCarcinoma, Non-Small-Cell Lung +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesA2 Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesA2 Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursKidney NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A